Head-to-head

TB-500 vs GHK-Cu

A field-by-field comparison of TB-500 and GHK-Cu drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — recovery & repair and skin & hair — so this page focuses on what each one actually does rather than which is "better".

TB-500 vs GHK-Cu at a glance

Attribute	TB-500	GHK-Cu
Category	Recovery & repair	Skin & hair
Evidence grade	Emerging	Moderate
Also known as	Thymosin Beta-4 fragment, TB4	Copper peptide, Glycyl-L-histidyl-L-lysine copper
Chain	7 amino acids (actin-binding domain of Tβ4)	Tripeptide (Gly-His-Lys) with copper(II)
Mechanism	Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines.	Delivers copper into cells and resets gene expression toward a younger profile, upregulating collagen, elastin and glycosaminoglycan synthesis while activating antioxidant defences and hair-follicle enlargement.
Reported benefits	Improved cell migration and wound closure in animal studies · Reported flexibility gains and reduced muscle spasm · Systemic action rather than site-specific, unlike BPC-157	Increased collagen and elastin production · Improved skin firmness and reduced fine lines · Hair-follicle stimulation · Accelerated wound healing
Reported side effects	Fatigue or head-rush after dosing · Injection-site reaction · Theoretical tumour-growth concern given angiogenic activity	Skin irritation or redness · Copper accumulation with excessive systemic use · Injection-site swelling
Half-life	Roughly 2–3 hours, with tissue effects lasting far longer	Not applicable topically; short systemically
Administration	Subcutaneous or intramuscular injection	Topical serum, microneedling adjunct or subcutaneous injection
Dosing overview	Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose	Topical 1–3% serum daily; injectable protocols vary widely
Storage	Powder at room temperature short term; reconstituted 2–8 °C for up to 30 days	Cool, dark place; the solution is characteristically deep blue
Legal status	Not approved for human use; sold for research purposes only.	Widely available as a cosmetic ingredient; injectable use is unapproved.

Key differences between TB-500 and GHK-Cu

Different categories, different goals

TB-500 is indexed under recovery & repair, while GHK-Cu sits under skin & hair. They are not substitutes for one another: TB-500 is described as "A synthetic version of the active region of thymosin beta-4, a naturally occurring wound-healing protein present in nearly all human cells." and GHK-Cu as "A naturally occurring copper-binding tripeptide with the best-supported cosmetic profile of any peptide, plus hair and wound-healing uses."

Mechanism of action

TB-500: Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines. GHK-Cu: Delivers copper into cells and resets gene expression toward a younger profile, upregulating collagen, elastin and glycosaminoglycan synthesis while activating antioxidant defences and hair-follicle enlargement.

Evidence quality is not equal

TB-500 carries a Emerging evidence grade and GHK-Cu a Moderate grade on this index. The grade describes the quality of published human data, not how well a compound works — GHK-Cu has the better-documented record of the two, and claims made about TB-500 rest on thinner human evidence.

Half-life and dosing frequency

TB-500 is listed at roughly 2–3 hours, with tissue effects lasting far longer; GHK-Cu at not applicable topically; short systemically. That difference is what drives the reported schedules: Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose versus Topical 1–3% serum daily; injectable protocols vary widely

Route of administration

TB-500 is administered by subcutaneous or intramuscular injection. GHK-Cu is administered by topical serum, microneedling adjunct or subcutaneous injection.

Legal and regulatory status differs

TB-500: Not approved for human use; sold for research purposes only. GHK-Cu: Widely available as a cosmetic ingredient; injectable use is unapproved. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

TB-500 is stored powder at room temperature short term; reconstituted 2–8 °c for up to 30 days. GHK-Cu is stored cool, dark place; the solution is characteristically deep blue.

What TB-500 and GHK-Cu have in common

On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — TB-500 and GHK-Cu share no identical values. They are compared here because they come up together in the same searches, not because they overlap.

Each compound in brief

TB-500

Recovery & repair · Emerging evidence

A synthetic version of the active region of thymosin beta-4, a naturally occurring wound-healing protein present in nearly all human cells.

Considerations: Frequently stacked with BPC-157 in anecdotal recovery protocols · Human data is limited to Tβ4 trials in dry-eye and cardiac injury · Prohibited by WADA at all times

GHK-Cu

Skin & hair · Moderate evidence

A naturally occurring copper-binding tripeptide with the best-supported cosmetic profile of any peptide, plus hair and wound-healing uses.

Considerations: Topical formulations are the safest starting point · Do not combine directly with vitamin C or strong acids in the same layer · Injectable use can cause significant flushing and irritation